These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 26259807)
41. Identification of novel inhibitors of extracellular signal-regulated kinase 2 based on the structure-based virtual screening. Park H; Bahn YJ; Jeong DG; Woo EJ; Kwon JS; Ryu SE Bioorg Med Chem Lett; 2008 Oct; 18(20):5372-6. PubMed ID: 18835158 [TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and characterization of "clickable" 4-anilinoquinazoline kinase inhibitors. Perera BG; Maly DJ Mol Biosyst; 2008 Jun; 4(6):542-50. PubMed ID: 18493651 [TBL] [Abstract][Full Text] [Related]
43. Pyridinylquinoxalines and pyridinylpyridopyrazines as lead compounds for novel p38 alpha mitogen-activated protein kinase inhibitors. Koch P; Jahns H; Schattel V; Goettert M; Laufer S J Med Chem; 2010 Feb; 53(3):1128-37. PubMed ID: 20078117 [TBL] [Abstract][Full Text] [Related]
44. The discovery and initial optimisation of pyrrole-2-carboxamides as inhibitors of p38alpha MAP kinase. Down K; Bamborough P; Alder C; Campbell A; Christopher JA; Gerelle M; Ludbrook S; Mallett D; Mellor G; Miller DD; Pearson R; Ray K; Solanke Y; Somers D Bioorg Med Chem Lett; 2010 Jul; 20(13):3936-40. PubMed ID: 20570148 [TBL] [Abstract][Full Text] [Related]
46. Displacement assay for the detection of stabilizers of inactive kinase conformations. Klüter S; Grütter C; Naqvi T; Rabiller M; Simard JR; Pawar V; Getlik M; Rauh D J Med Chem; 2010 Jan; 53(1):357-67. PubMed ID: 19928858 [TBL] [Abstract][Full Text] [Related]
47. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo. Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647 [TBL] [Abstract][Full Text] [Related]
48. 2-Acylaminopyridin-4-ylimidazoles as p38 MAP kinase inhibitors: Design, synthesis, and biological and metabolic evaluations. Ziegler K; Hauser DR; Unger A; Albrecht W; Laufer SA ChemMedChem; 2009 Nov; 4(11):1939-48. PubMed ID: 19731280 [TBL] [Abstract][Full Text] [Related]
49. p38 Mitogen-activated protein kinase and extracellular signal-regulated kinase signaling pathways are not essential regulators of formyl peptide-stimulated p47(phox) activation in neutrophils. Tsai YR; Wang YJ; Lee MR; Hsu MF; Wang JP Eur J Pharmacol; 2013 Feb; 701(1-3):96-105. PubMed ID: 23348708 [TBL] [Abstract][Full Text] [Related]
50. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Ravindra GK; Achaiah G; Sastry GN Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839 [TBL] [Abstract][Full Text] [Related]
52. Discovery of MEK/PI3K dual inhibitor via structure-based virtual screening. Park H; Lee S; Hong S Bioorg Med Chem Lett; 2012 Aug; 22(15):4946-50. PubMed ID: 22771009 [TBL] [Abstract][Full Text] [Related]
53. Lead Diversification 2: application to P38, gMTP and lead compounds. Masood MA; Bazin M; Bunnage ME; Calabrese A; Cox M; Fancy SA; Farrant E; Pearce DW; Perez M; Hitzel L; Peakman T Bioorg Med Chem Lett; 2012 Jan; 22(2):1255-62. PubMed ID: 22172703 [TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase. Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708 [TBL] [Abstract][Full Text] [Related]
55. Synthesis and SAR of p38alpha MAP kinase inhibitors based on heterobicyclic scaffolds. Murali Dhar TG; Wrobleski ST; Lin S; Furch JA; Nirschl DS; Fan Y; Todderud G; Pitt S; Doweyko AM; Sack JS; Mathur A; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2007 Sep; 17(18):5019-24. PubMed ID: 17664068 [TBL] [Abstract][Full Text] [Related]
56. Sequence, structure, and active site analyses of p38 MAP kinase: exploiting DFG-out conformation as a strategy to design new type II leads. Badrinarayan P; Sastry GN J Chem Inf Model; 2011 Jan; 51(1):115-29. PubMed ID: 21141877 [TBL] [Abstract][Full Text] [Related]
57. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy. Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470 [TBL] [Abstract][Full Text] [Related]
58. Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease. Pinsetta FR; Taft CA; de Paula da Silva CH J Biomol Struct Dyn; 2014; 32(7):1047-63. PubMed ID: 23805842 [TBL] [Abstract][Full Text] [Related]